Black Seed
Also sold as: Nigella sativa · Black cumin · Black seed oil · Thymoquinone
An oilseed botanical studied mainly for glucose, lipid and blood-pressure markers. Whole seeds, ordinary oil and thymoquinone-standardized oil are distinct preparations.
Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Longevity: Human lifespan extension is unestablished; improvements in metabolic surrogate markers do not establish longer life.
REALITY CHECK // The best-supported claims concern metabolic markers, not a universal cure or a calming drug. The dossier contains no human anxiety RCT, and nano-delivery pharmacokinetics do not establish better clinical outcomes. Long-term cardiovascular and lifespan benefits remain untested.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
01 // STUDIED_DOSE_RANGE
Trial exposure, not a prescription
Trials typically used 0.5-5 g/day seed oil or 1-3 g/day ground seeds over roughly 6-12 weeks; Hashimoto trials commonly lasted 8 weeks. A seasonal-allergy RCT used oil standardized to 5% thymoquinone; its exact oil dose is not supplied here.
02 // TIMING_&_MATRIX
Preparation matters
Food may improve tolerability of pungent oil; lipophilic thymoquinone has variable absorption. There is no established optimal time of day.
03 // EVALUATION_WINDOW
Measure the relevant outcome
Metabolic studies usually assessed 6-12 weeks; immediate subjective calm does not predict laboratory or long-term outcomes.
04 // SAFETY_&_QUALITY_GATE
Check medicines and the label
Require identity and thymoquinone testing; review diabetes, pressure, anticoagulant and thyroid therapy before concentrated use.
UPPER LIMIT // No established EFSA or NIH tolerable upper intake level is supplied for black seed or thymoquinone. Trial doses are not a safety ceiling; long-term high-dose safety is poorly characterized.
Summary
RCT meta-analyses consistently favor glucose, lipids and blood pressure, especially in adults with metabolic disease, but most trials are small, short and heterogeneous. Blood-pressure changes are only a few mmHg; clinical cardiovascular events and general mortality have not been tested. Mood and calming claims remain anecdotes.
Mechanism
Thymoquinone and other seed constituents have anti-inflammatory and metabolic activity. NF-kB, cytokine and antioxidant mechanisms are largely preclinical; whole-seed effects cannot be assigned to isolated thymoquinone.
Typical studied dose
Trials typically used 0.5-5 g/day seed oil or 1-3 g/day ground seeds over roughly 6-12 weeks; Hashimoto trials commonly lasted 8 weeks. A seasonal-allergy RCT used oil standardized to 5% thymoquinone; its exact oil dose is not supplied here.
Upper limit
No established EFSA or NIH tolerable upper intake level is supplied for black seed or thymoquinone. Trial doses are not a safety ceiling; long-term high-dose safety is poorly characterized.
Popular stacks with Black Seed
Not enough stack data yet. A combination with Black Seed appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Cold-pressed seed oil Best for: Oil preparations with disclosed composition. |
Unstandardized: active content unknown | 500–5000 mg | Thymoquinone is lipophilic with low, variable systemic exposure. Pungent taste, nausea, reflux or loose stools. |
Caution CAUTION Thymoquinone commonly varies around 0.2-1%; no marker conversion is possible without a specific label assay. The cited trial used standardized oil, not all ordinary oils. |
| Oil standardized to 5% thymoquinone Best for: Matching the specific seasonal-allergy preparation. |
Extract weight · ~5% marker | no comparable trial range | Standardization improves repeatability, not proven superior absorption. Usually tolerated in short trials. |
Studied standard REFERENCE The calculator compares full oil mass; 5% is the marker fraction. Exact trial dose must be recovered before a numerical comparison. |
| Ground whole seeds Best for: Whole-seed trial matching. |
Extract weight · marker not quantified | 1000–3000 mg | Whole-seed matrix; used in thyroid and metabolic studies. Generally tolerated as food; individual GI effects vary. |
Good option GOOD The mass is whole seed, not pure thymoquinone; marker percentage is unknown. |
| Thymoquinone nanocarriers Best for: Research context. |
Unstandardized: active content unknown | no comparable trial range | Experimental nanocarriers improve pharmacokinetics; the cited pharmacokinetic study is preclinical. Human comparative tolerance is unestablished. |
Caution CAUTION Higher exposure is not proof of a superior health outcome or long-term safety. |
Common label traps
- TRAP_01 // A cure for everything
Evidence is concentrated in surrogate metabolic outcomes; autoimmune, respiratory and GI indications have much smaller studies. - TRAP_02 // Natural replacement for diabetes or pressure treatment
Effects can add to medicines and cause excessive glucose or pressure lowering; do not self-reduce prescribed treatment. - TRAP_03 // Calming like a benzodiazepine
The dossier indexes no human anxiety RCT; anecdotes include irritability and palpitations as well as calm. - TRAP_04 // Higher thymoquinone always works better
Preparations differ; repeatable composition is useful, while clinical superiority and safe chronic high doses are unestablished.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- LIPIDS Moderate · benefit
RCT meta-analyses favor lower total cholesterol, LDL and triglycerides over weeks in adults, particularly with dyslipidemia; HDL is inconsistent and effect sizes vary by product.
PMID 26875640 PMID 38777430 - GLUCOSE_CONTROL Moderate · benefit
RCT syntheses favor fasting glucose, HbA1c and HOMA-IR in metabolic disease over roughly 8 weeks to 3 months; small heterogeneous trials leave magnitude uncertain.
PMID 39181437 PMID 29154069 PMID 40210172 PMID 41858302 - BLOOD_PRESSURE Moderate · benefit
RCT meta-analyses show small reductions of a few mmHg in adults; not evidence of prevention of heart attacks or strokes.
PMID 27512971 PMID 37341696 - BODY_WEIGHT Limited · benefit
Short, heterogeneous trials in overweight/metabolic populations show small changes in weight, BMI or waist; not comparable to obesity pharmacotherapy.
PMID 29559374 PMID 31793087 - METABOLIC_SYNDROME Moderate · benefit
A GRADE-assessed dose-response synthesis of 82 RCTs supports several cardiovascular risk markers, with no established effect on clinical events.
PMID 40714301 PMID 39002164 PMID 38265398 - ASTHMA Limited · benefit
A small heterogeneous clinical meta-analysis suggests symptom/control improvement as an adjunct; the ovalbumin-model review is preclinical, not human efficacy evidence.
PMID 31892440 PMID 40839182 - ALLERGIC_RHINITIS Limited · benefit
Small RCTs and a meta-analysis suggest symptom benefit; one trial used 5% thymoquinone oil. Do not generalize to arbitrary oils.
PMID 39372205 PMID 20947211 PMID 39121267 PMID 14669258 - HASHIMOTO_MARKERS Limited · benefit
Small clinical studies report thyroid, lipid and adhesion-marker changes, including an 8-week setting; the T-cell essential-oil study is in vitro. No cure or medicine replacement is established.
PMID 27852303 PMID 32359745 PMID 29587770 PMID 37371976 - FATTY_LIVER_MARKERS Limited · benefit
Small clinical trials and a systematic review suggest improvements in steatosis, aminotransferases and inflammatory markers in NAFLD/MASLD; hard outcomes remain untested.
PMID 36698733 PMID 30639231 PMID 31126557 PMID 31293021 - RHEUMATOID_ARTHRITIS Limited · benefit
A small clinical base suggests inflammatory-marker and symptom changes as an adjunct; does not replace disease-modifying therapy.
PMID 32274788 PMID 27247920 - COVID_19 Limited · benefit
A randomized-trial meta-analysis letter suggests a contextual mortality signal with few heterogeneous trials and bias concerns; abstract-level detail is absent in the catalog. Not a home infection protocol.
PMID 36757063 - H_PYLORI_DYSPEPSIA Limited · benefit
Small mixed studies suggest some eradication/symptom effects, including about 2 g/day in a comparison and a honey-oil formulation. Not equivalent to standard eradication therapy.
PMID 20616418 PMID 26386381 PMID 31916648 - MALE_FERTILITY Anecdotal · benefit
One single-blind trial used palm pollen plus black seed pollen; isolated black seed benefits on testosterone or fertility cannot be inferred.
PMID 36617207
Reader questions
Does black seed oil reliably calm anxiety?
No human anxiety RCT is indexed in this dossier. Reports of calm, irritability or palpitations are anecdotes, not reliable treatment effects.
Which form makes dose comparisons meaningful?
Check the plant, oil versus whole seed, thymoquinone assay and a batch certificate. A 5% oil gives a repeatable marker exposure; it is not interchangeable milligram-for-milligram with ordinary oil or seeds.
Can I reduce my diabetes or blood-pressure medicine?
Only the treating clinician should change treatment. Additive glucose or pressure lowering is precisely why monitoring matters.
Is long-term high-dose use safe?
Human long-term safety is insufficiently characterized. GI effects are known; the dossier has no verified human hepatotoxicity case establishing a rate. New weakness or palpitations warrant stopping and review.
What about pregnancy or Hashimoto treatment?
Avoid supplemental use in pregnancy/breastfeeding. With Hashimoto disease or levothyroxine, review the product with the clinician and monitor thyroid markers.
Stack interactions
- Caution Glucose-lowering medicines / berberine [CAUTION]
Metabolic trials support glucose lowering, so additive effects are plausible. Glibenclamide potentiation is a rat-model finding, not a quantified human interaction.
PMID 29154069 PMID 40179858 - Caution Antihypertensives / beetroot / garlic [CAUTION]
Blood-pressure lowering may add to treatment; monitor rather than assuming botanical combinations are neutral.
PMID 37341696 PMID 27512971 - Caution Warfarin and phenytoin [CAUTION]
Thymoquinone can alter drug metabolism in laboratory interaction studies; clinical relevance requires pharmacist review, especially with narrow therapeutic indices.
PMID 35921950 PMID 34998822 - Caution Levothyroxine / thyroid supplements [CAUTION]
Small Hashimoto trials changed thyroid markers. Review supplementation with the treating clinician and follow TSH rather than changing medicine independently.
PMID 27852303
Red flags: interactions and who should avoid it
Interactions
May add to glucose-lowering and blood-pressure medicines. Thymoquinone-warfarin and thymoquinone-phenytoin interaction signals are laboratory data, not confirmed clinical event rates. Other glucose-lowering, hypotensive or antiplatelet supplements warrant medication review; thyroid treatment requires monitoring.
Avoid or ask a doctor first if
Avoid supplemental doses during pregnancy or breastfeeding and unsupervised use in children. Seek advice with diabetes medication, anticoagulation, surgery, liver/kidney disease or narrow-therapeutic-index medicines. Nausea, heartburn and loose stools occur; stop and seek review for new palpitations, marked weakness or other concerning symptoms.
Sources (PubMed, 39)
- Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials.
PMID 26875640 · 2016 · systematic review / meta-analysisRCT meta-analyses favor lower total cholesterol, LDL and triglycerides over weeks in adults, particularly with dyslipidemia; HDL is inconsistent and effect sizes vary by product.
- Effects of Nigella sativa supplementation on lipid profiles in adults: An updated systematic review and meta-analysis of randomized controlled trials.
PMID 38777430 · 2024 · systematic review / meta-analysisRCT meta-analyses favor lower total cholesterol, LDL and triglycerides over weeks in adults, particularly with dyslipidemia; HDL is inconsistent and effect sizes vary by product.
- Does Nigella sativa supplementation improve cardiovascular disease risk factors? A comprehensive GRADE-assessed systematic review and dose-response meta-analysis of 82 randomized controlled trials.
PMID 40714301 · 2025 · systematic review / meta-analysisA GRADE-assessed dose-response synthesis of 82 RCTs supports several cardiovascular risk markers, with no established effect on clinical events.
- The effect of Nigella sativa supplementation on glycemic status in adults: An updated systematic review and meta-analysis of randomized controlled trials.
PMID 39181437 · 2024 · systematic review / meta-analysisRCT syntheses favor fasting glucose, HbA1c and HOMA-IR in metabolic disease over roughly 8 weeks to 3 months; small heterogeneous trials leave magnitude uncertain.
- Nigella sativa improves glucose homeostasis and serum lipids in type 2 diabetes: A systematic review and meta-analysis.
PMID 29154069 · 2017 · systematic review / meta-analysisRCT syntheses favor fasting glucose, HbA1c and HOMA-IR in metabolic disease over roughly 8 weeks to 3 months; small heterogeneous trials leave magnitude uncertain.
- Effects of black seed (Nigella sativa L.) on cardiometabolic indices in type 2 diabetic patients: A systematic review and meta-analysis of RCTs.
PMID 40210172 · 2025 · systematic review / meta-analysisRCT syntheses favor fasting glucose, HbA1c and HOMA-IR in metabolic disease over roughly 8 weeks to 3 months; small heterogeneous trials leave magnitude uncertain.
- The Effect of Nigella sativa Supplementation on Cardiometabolic Health in Patients With Metabolic Diseases: A GRADE-Assessed Systematic Review and Meta-Analysis.
PMID 41858302 · 2026 · systematic review / meta-analysisRCT syntheses favor fasting glucose, HbA1c and HOMA-IR in metabolic disease over roughly 8 weeks to 3 months; small heterogeneous trials leave magnitude uncertain.
- A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure.
PMID 27512971 · 2016 · systematic review / meta-analysisRCT meta-analyses show small reductions of a few mmHg in adults; not evidence of prevention of heart attacks or strokes.
- Antihypertensive effects of Nigella sativa supplementation: An updated systematic review and meta-analysis of randomized controlled trials.
PMID 37341696 · 2023 · systematic review / meta-analysisRCT meta-analyses show small reductions of a few mmHg in adults; not evidence of prevention of heart attacks or strokes.
- The effects of Nigella sativa L. on obesity: A systematic review and meta-analysis.
PMID 29559374 · 2018 · systematic review / meta-analysisShort, heterogeneous trials in overweight/metabolic populations show small changes in weight, BMI or waist; not comparable to obesity pharmacotherapy.
- Effect of the herbal medicines in obesity and metabolic syndrome: A systematic review and meta-analysis of clinical trials.
PMID 31793087 · 2020 · systematic review / meta-analysisShort, heterogeneous trials in overweight/metabolic populations show small changes in weight, BMI or waist; not comparable to obesity pharmacotherapy.
- Systematic Review of Randomized Controlled Trials in Uses of Nigella Sativa (Black Seed) in Metabolic Syndrome.
PMID 39002164 · 2024 · systematic review / meta-analysisA GRADE-assessed dose-response synthesis of 82 RCTs supports several cardiovascular risk markers, with no established effect on clinical events.
- Effect of Nigella sativa Consumption on Lipid Profile and Glycemic Index in Patients with Metabolic Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PMID 38265398 · 2025 · systematic review / meta-analysisA GRADE-assessed dose-response synthesis of 82 RCTs supports several cardiovascular risk markers, with no established effect on clinical events.
- The influence of Nigella sativa for asthma control: A meta-analysis.
PMID 31892440 · 2020 · systematic review / meta-analysisA small heterogeneous clinical meta-analysis suggests symptom/control improvement as an adjunct; the ovalbumin-model review is preclinical, not human efficacy evidence.
- Effects of Nigella sativa and its constituents on inflammatory markers in ovalbumin-induced asthma model: a preclinical systematic review and meta-analysis.
PMID 40839182 · 2025 · preclinical systematic review / experimental studyA small heterogeneous clinical meta-analysis suggests symptom/control improvement as an adjunct; the ovalbumin-model review is preclinical, not human efficacy evidence.
- Meta-analysis of randomized controlled trials assessing the efficacy of nigella sativa supplementation for allergic rhinitis treatment.
PMID 39372205 · 2024 · systematic review / meta-analysisSmall RCTs and a meta-analysis suggest symptom benefit; one trial used 5% thymoquinone oil. Do not generalize to arbitrary oils.
- Herbal treatment of allergic rhinitis: the use of Nigella sativa.
PMID 20947211 · 2011 · randomized controlled trialSmall RCTs and a meta-analysis suggest symptom benefit; one trial used 5% thymoquinone oil. Do not generalize to arbitrary oils.
- A randomized, double-blind, placebo-controlled study to evaluate the benefits of a standardized Nigella sativa oil containing 5% thymoquinone in reducing the symptoms of seasonal allergy.
PMID 39121267 · 2024 · randomized controlled trialSmall RCTs and a meta-analysis suggest symptom benefit; one trial used 5% thymoquinone oil. Do not generalize to arbitrary oils.
- Effect of Nigella sativa (black seed) on subjective feeling in patients with allergic diseases.
PMID 14669258 · 2003 · randomized controlled trialSmall RCTs and a meta-analysis suggest symptom benefit; one trial used 5% thymoquinone oil. Do not generalize to arbitrary oils.
- The effects of Nigella sativa on thyroid function, serum Vascular Endothelial Growth Factor (VEGF) - 1, Nesfatin-1 and anthropometric features in patients with Hashimoto's thyroiditis: a randomized controlled trial.
PMID 27852303 · 2016 · randomized controlled trialSmall clinical studies report thyroid, lipid and adhesion-marker changes, including an 8-week setting; the T-cell essential-oil study is in vitro. No cure or medicine replacement is established.
- The effects of powdered black cumin seeds on markers of oxidative stress, intracellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in patients with Hashimoto's thyroiditis.
PMID 32359745 · 2020 · randomized controlled trialSmall clinical studies report thyroid, lipid and adhesion-marker changes, including an 8-week setting; the T-cell essential-oil study is in vitro. No cure or medicine replacement is established.
- Powdered black cumin seeds strongly improves serum lipids, atherogenic index of plasma and modulates anthropometric features in patients with Hashimoto's thyroiditis.
PMID 29587770 · 2018 · randomized controlled trialSmall clinical studies report thyroid, lipid and adhesion-marker changes, including an 8-week setting; the T-cell essential-oil study is in vitro. No cure or medicine replacement is established.
- The Impact of Nigella sativa Essential Oil on T Cells in Women with Hashimoto's Thyroiditis.
PMID 37371976 · 2023 · in vitro studySmall clinical studies report thyroid, lipid and adhesion-marker changes, including an 8-week setting; the T-cell essential-oil study is in vitro. No cure or medicine replacement is established.
- Nigella sativa supplementation and non-alcoholic fatty liver disease: A systematic review of clinical trials.
PMID 36698733 · 2023 · systematic review / meta-analysisSmall clinical trials and a systematic review suggest improvements in steatosis, aminotransferases and inflammatory markers in NAFLD/MASLD; hard outcomes remain untested.
- Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial.
PMID 30639231 · 2019 · randomized controlled trialSmall clinical trials and a systematic review suggest improvements in steatosis, aminotransferases and inflammatory markers in NAFLD/MASLD; hard outcomes remain untested.
- Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial.
PMID 31126557 · 2019 · randomized controlled trialSmall clinical trials and a systematic review suggest improvements in steatosis, aminotransferases and inflammatory markers in NAFLD/MASLD; hard outcomes remain untested.
- The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial.
PMID 31293021 · 2019 · randomized controlled trialSmall clinical trials and a systematic review suggest improvements in steatosis, aminotransferases and inflammatory markers in NAFLD/MASLD; hard outcomes remain untested.
- A Systematic Review of the Potential Effects of Nigella sativa on Rheumatoid Arthritis.
PMID 32274788 · 2020 · systematic review / meta-analysisA small clinical base suggests inflammatory-marker and symptom changes as an adjunct; does not replace disease-modifying therapy.
- Effects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial.
PMID 27247920 · 2016 · randomized controlled trialA small clinical base suggests inflammatory-marker and symptom changes as an adjunct; does not replace disease-modifying therapy.
- The effect of Nigella sativa on the risk of mortality in patients with COVID-19: A systematic review and meta-analysis of randomized trials.
PMID 36757063 · 2024 · systematic review / meta-analysisA randomized-trial meta-analysis letter suggests a contextual mortality signal with few heterogeneous trials and bias concerns; abstract-level detail is absent in the catalog. Not a home infection protocol.
- Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia.
PMID 20616418 · 2010 · randomized controlled trialSmall mixed studies suggest some eradication/symptom effects, including about 2 g/day in a comparison and a honey-oil formulation. Not equivalent to standard eradication therapy.
- Efficacy and safety of honey based formulation of Nigella sativa seed oil in functional dyspepsia: A double blind randomized controlled clinical trial.
PMID 26386381 · 2015 · randomized controlled trialSmall mixed studies suggest some eradication/symptom effects, including about 2 g/day in a comparison and a honey-oil formulation. Not equivalent to standard eradication therapy.
- The beneficial health effects of Nigella sativa on Helicobacter pylori eradication, dyspepsia symptoms, and quality of life in infected patients: A pilot study.
PMID 31916648 · 2020 · randomized controlled trialSmall mixed studies suggest some eradication/symptom effects, including about 2 g/day in a comparison and a honey-oil formulation. Not equivalent to standard eradication therapy.
- The Effect of Palm Pollen and Black Seed Pollen on Male Sex Hormones and Sperm Quality: A Single-Blind, Placebo-Controlled Clinical Trial Study.
PMID 36617207 · 2023 · randomized controlled trialOne single-blind trial used palm pollen plus black seed pollen; isolated black seed benefits on testosterone or fertility cannot be inferred.
- Nanocarriers: more than tour de force for thymoquinone.
PMID 32077770 · 2020 · narrative reviewExperimental nanocarriers improve pharmacokinetics; the cited pharmacokinetic study is preclinical. Higher exposure is not proof of a superior health outcome or long-term safety.
- Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration.
PMID 23818776 · 2013 · animal studyExperimental nanocarriers improve pharmacokinetics; the cited pharmacokinetic study is preclinical. Higher exposure is not proof of a superior health outcome or long-term safety.
- Black seed oil boosts antidiabetic activity of glibenclamide: development of solidified self nanoemulsifying drug delivery system and evaluation in Streptozotocin-Induced diabetic rat model.
PMID 40179858 · 2025 · animal studyMetabolic trials support glucose lowering, so additive effects are plausible. Glibenclamide potentiation is a rat-model finding, not a quantified human interaction.
- Potential food-drug interaction risk of thymoquinone with warfarin.
PMID 35921950 · 2022 · in vitro studyThymoquinone can alter drug metabolism in laboratory interaction studies; clinical relevance requires pharmacist review, especially with narrow therapeutic indices.
- Potential herb-drug interaction risk of thymoquinone and phenytoin.
PMID 34998822 · 2022 · in vitro studyThymoquinone can alter drug metabolism in laboratory interaction studies; clinical relevance requires pharmacist review, especially with narrow therapeutic indices.
Community comments
No approved comments yet. Comments are held for moderation.